Terms: = Breast cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207
7914 results:
1. Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors.
Fu XP; Ji CY; Tang WQ; Yu TT; Luo L
Clin Exp Med; 2024 May; 24(1):93. PubMed ID: 38693424
[TBL] [Abstract] [Full Text] [Related]
2. Development of a Novel, Potent, and Selective Sialyltransferase Inhibitor for Suppressing cancer Metastasis.
Tsai HE; Chen CL; Chang TT; Fu CW; Chen WC; Perez SJLP; Hsiao PW; Tai MH; Li WS
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673867
[TBL] [Abstract] [Full Text] [Related]
3. Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer.
Han JY; Che N; Mo J; Zhang DF; Liang XH; Dong XY; Zhao XL; Sun BC
BMC Cancer; 2024 Apr; 24(1):532. PubMed ID: 38671389
[TBL] [Abstract] [Full Text] [Related]
4. CircPDE5A-encoded novel regulator of the PI3K/akt pathway inhibits esophageal squamous cell carcinoma progression by promoting USP14-mediated de-ubiquitination of PIK3IP1.
Lei K; Liang R; Liang J; Lu N; Huang J; Xu K; Tan B; Wang K; Liang Y; Wang W; Lin H; Wang M
J Exp Clin Cancer Res; 2024 Apr; 43(1):124. PubMed ID: 38658954
[TBL] [Abstract] [Full Text] [Related]
5. Elongin B promotes breast cancer progression by ubiquitinating tumor suppressor p14/ARF.
Sui XY; Ma XY; Hou Y; Cao SW; Wang ZQ; Jia LJ; Fan L; Shao ZM; Zhang WJ
Cell Biol Toxicol; 2024 Apr; 40(1):24. PubMed ID: 38653919
[TBL] [Abstract] [Full Text] [Related]
6. Tumor-associated macrophage subtypes on cancer immunity along with prognostic analysis and SPP1-mediated interactions between tumor cells and macrophages.
Xu L; Chen Y; Liu L; Hu X; He C; Zhou Y; Ding X; Luo M; Yan J; Liu Q; Li H; Lai D; Zou Z
PLoS Genet; 2024 Apr; 20(4):e1011235. PubMed ID: 38648200
[TBL] [Abstract] [Full Text] [Related]
7. Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1-3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study.
Bae SJ; Chun JW; Lee SB; Ryu JM; Nam SJ; Jeong J; Park HS; Ahn SG
Breast Cancer Res; 2024 Apr; 26(1):66. PubMed ID: 38632652
[TBL] [Abstract] [Full Text] [Related]
8. Correlation between sentinel lymph node biopsy and non-sentinel lymph node metastasis in patients with cN0 breast carcinoma: comparison of invasive ductal carcinoma and invasive lobular carcinoma.
Cipolla C; Lupo S; Grassi N; Tutino G; Greco M; Eleonora D; Gebbia V; Valerio MR
World J Surg Oncol; 2024 Apr; 22(1):100. PubMed ID: 38627759
[TBL] [Abstract] [Full Text] [Related]
9. ANXA9 facilitates S100A4 and promotes breast cancer progression through modulating STAT3 pathway.
Zhou X; Zhao J; Yan T; Ye D; Wang Y; Zhou B; Liu D; Wang X; Zheng W; Zheng B; Qian F; Li Y; Li D; Fang L
Cell Death Dis; 2024 Apr; 15(4):260. PubMed ID: 38609357
[TBL] [Abstract] [Full Text] [Related]
10. Active substance and mechanisms of Actinidia chinensis Planch for the treatment of breast cancer was explored based on network pharmacology and in silico study.
Xu Y; Yang J; Han X; Gan C; Wei X
Medicine (Baltimore); 2024 Apr; 103(15):e37829. PubMed ID: 38608062
[TBL] [Abstract] [Full Text] [Related]
11. Nutritional Sources and Anticancer Potential of Phenethyl Isothiocyanate: Molecular Mechanisms and Therapeutic Insights.
M Ezzat S; M Merghany R; M Abdel Baki P; Ali Abdelrahim N; M Osman S; A Salem M; Peña-Corona SI; Cortés H; Kiyekbayeva L; Leyva-Gómez G; Sharifi-Rad J; Calina D
Mol Nutr Food Res; 2024 Apr; 68(8):e2400063. PubMed ID: 38600885
[TBL] [Abstract] [Full Text] [Related]
12. Photobiomodulation therapy moderates cancer cachexia-associated muscle wasting through activating PI3K/akt/FoxO3a pathway.
Li Y; Chen Y; Liao Y; Huang T; Tang Q; He C; Xu L; Chang H; Li H; Liu Q; Lai D; Xia Q; Zou Z
Apoptosis; 2024 Jun; 29(5-6):663-680. PubMed ID: 38598070
[TBL] [Abstract] [Full Text] [Related]
13. akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises.
Pervanidis KA; D'Angelo GD; Weisner J; Brandherm S; Rauh D
J Med Chem; 2024 Apr; 67(8):6052-6063. PubMed ID: 38592948
[TBL] [Abstract] [Full Text] [Related]
14. Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.
Ali K; Nabeel M; Mohsin F; Iqtedar M; Islam M; Rasool MF; Hashmi FK; Hussain SA; Saeed H
Med Oncol; 2024 Apr; 41(5):112. PubMed ID: 38592510
[TBL] [Abstract] [Full Text] [Related]
15. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
16. The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features.
Salaün H; Djerroudi L; Haik L; Schnitzler A; Bataillon G; Deniziaut G; Bièche I; Vincent-Salomon A; Debled M; Cottu P
J Pathol Clin Res; 2024 May; 10(3):e12372. PubMed ID: 38563252
[TBL] [Abstract] [Full Text] [Related]
17. The PI3K/akt/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances.
Khorasani ABS; Hafezi N; Sanaei MJ; Jafari-Raddani F; Pourbagheri-Sigaroodi A; Bashash D
Cell Biochem Funct; 2024 Apr; 42(3):e3998. PubMed ID: 38561964
[TBL] [Abstract] [Full Text] [Related]
18. Methyl-CpG binding domain protein 2 (Mbd2) drives breast cancer progression through the modulation of epithelial-to-mesenchymal transition.
Mahmood N; Arakelian A; Szyf M; Rabbani SA
Exp Mol Med; 2024 Apr; 56(4):959-974. PubMed ID: 38556549
[TBL] [Abstract] [Full Text] [Related]
19. Optimal targeting of PI3K-akt and mTOR in advanced oestrogen receptor-positive breast cancer.
Browne IM; André F; Chandarlapaty S; Carey LA; Turner NC
Lancet Oncol; 2024 Apr; 25(4):e139-e151. PubMed ID: 38547898
[TBL] [Abstract] [Full Text] [Related]
20. Decision regret of cancer patients after radiotherapy: results from a cross-sectional observational study at a large tertiary cancer center in Germany.
Rühle A; Wieland L; Hinz A; Mehnert-Theuerkauf A; Nicolay NH; Seidel C
J Cancer Res Clin Oncol; 2024 Mar; 150(3):167. PubMed ID: 38546873
[TBL] [Abstract] [Full Text] [Related]
[Next]
